Severe forms of neurocysticercosis: treatment with albendazole
- PMID: 8736150
- DOI: 10.1590/s0004-282x1996000100014
Severe forms of neurocysticercosis: treatment with albendazole
Abstract
Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs. Multiple symptoms were observed in 90.9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.
Similar articles
-
Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle.J Neurosurg. 1997 Jul;87(1):29-33. doi: 10.3171/jns.1997.87.1.0029. J Neurosurg. 1997. PMID: 9202261 Clinical Trial.
-
Neurocysticercosis: treatment with albendazole and dextrochloropheniramine.Trans R Soc Trop Med Hyg. 1989 May-Jun;83(3):377-83. doi: 10.1016/0035-9203(89)90509-9. Trans R Soc Trop Med Hyg. 1989. PMID: 2617585
-
Cerebral and subcutaneous cysticercosis treated with albendazole.Int J Dermatol. 1995 Aug;34(8):574-9. doi: 10.1111/j.1365-4362.1995.tb02959.x. Int J Dermatol. 1995. PMID: 7591443
-
[Cerebral cysticercosis treated by albendazole: development of cerebral magnetic resonance imaging].Rev Neurol (Paris). 1994 Oct;150(10):709-12. Rev Neurol (Paris). 1994. PMID: 7792479 Review. French.
-
Pharmacokinetic optimisation of the treatment of neurocysticercosis.Clin Pharmacokinet. 1998 Jun;34(6):503-15. doi: 10.2165/00003088-199834060-00006. Clin Pharmacokinet. 1998. PMID: 9646011 Review.
Cited by
-
The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.Trans R Soc Trop Med Hyg. 2018 Feb 1;112(2):73-80. doi: 10.1093/trstmh/try023. Trans R Soc Trop Med Hyg. 2018. PMID: 29579308 Free PMC article. Clinical Trial.
-
Reversible dementia due to neurocysticercosis: Improvement of the racemose type with antihistamines.Dement Neuropsychol. 2015 Jan-Mar;9(1):85-90. doi: 10.1590/S1980-57642015DN91000014. Dement Neuropsychol. 2015. PMID: 29213947 Free PMC article.
-
Current consensus guidelines for treatment of neurocysticercosis.Clin Microbiol Rev. 2002 Oct;15(4):747-56. doi: 10.1128/CMR.15.4.747-756.2002. Clin Microbiol Rev. 2002. PMID: 12364377 Free PMC article. Review.
-
Diagnosis and treatment of neurocysticercosis.Nat Rev Neurol. 2011 Sep 13;7(10):584-94. doi: 10.1038/nrneurol.2011.135. Nat Rev Neurol. 2011. PMID: 21912406 Free PMC article. Review.
-
Corticosteroid use in neurocysticercosis.Expert Rev Neurother. 2011 Aug;11(8):1175-83. doi: 10.1586/ern.11.86. Expert Rev Neurother. 2011. PMID: 21797658 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical